- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608983
Hydrocolloids as Functional Food Ingredients for Gut Health (HYFFI)
Seaweeds are a natural source of nutrients, and dependent on the variety, are rich in dietary fibre, proteins, essential vitamins and minerals. However this resource is highly underexploited. Countries such as Japan, China, North and South Korea are large consumers of edible seaweed while exposure in Western countries is much lower and mainly as industrially extracted seaweed derivatives, a common additive in many food and healthcare products. Seaweeds have been associated with a number of human gut promoting health benefits such as decreasing faecal transit time through the gastrointestinal tract thus preventing constipation and resulting in a reduced exposure to harmful substances (decreasing colon cancer risk). These health benefits can be attributed to seaweeds high dietary fibre content. Interestingly, the food and healthcare industry already utilize seaweed-extracted fibre in the manufacturing process thus steering the way forward towards the development of novel functional food products. These seaweed-extracted fibres are high molecular weight polysaccharides known as hydrocolloids and are non-digestible by humans, hence classified as dietary fibre.
Traditionally, seaweed derived polysaccharides (hydrocolloids) have been used to provide thickening and gelling functionality to food stuffs and other industrial applications however there is emerging evidence to show that lower molecular weight polysaccharides and oligosaccharides derived from these hydrocolloids can also act as a source of soluble fibre and may have prebiotic activity. Recent developments in Japan and Korea have lead to the commercial availability of products containing low molecular weight seaweed derived fibre. There is also some evidence for the beneficial effects of seaweed derived fibre in other key health areas such as cardiovascular health, cancer, diabetes and obesity. However, relatively little is known about the chemical, physio-chemical and fermentation characteristics of seaweed fibre in the human gut. Some hydrocolloids, notably guar gum (plant source), have also been employed for their health promoting properties in the areas of glucose tolerance and cholesterol lowering. However the use of hydrocolloids as functional food ingredients with health benefits for consumers has been rather limited and has focused more on uses in products for diabetics.
It is particularly in the area of gut health that small and medium-sized enterprises (SMEs) involved in hydrocolloid production and processing, can enter the functional food ingredients market by using innovative processing technology. The total dietary fibre content of seaweed can be as high as 75% of the total dry weight and a high proportion of this is soluble. The fibre component essentially comprises the structural polysaccharides i.e. alginate and fucoidan in brown seaweeds, carrageenan, agar and porphyran in red seaweeds and ulvan in green seaweeds. As these fibres are primarily soluble, they form viscous gels as they pass through the gastrointestinal tract. Some of the fibre is fermented in the lower intestine but in general, soluble and insoluble seaweed fibre tends to pass through the gut without being digested. In its natural form as part of the seaweed plant, this fibre is typically high in molecular weight and passes through the gut too rapidly for the gut microflora to utilize it to any great extent. There is therefore a necessity to develop lower molecular weight forms that are more soluble and can be added at higher concentrations to food products without affecting the sensory properties of the product.
The overall aim of the project is to realize an opportunity to produce low molecular weight polysaccharides (LMWP) from alginate- and agar-bearing seaweeds for applications in food & health. The two effective agar and alginate LMWPs, identified by in vitro studies, will be selected for assessment of prebiotic activity in a feeding trial in human volunteers (Ulster University) as part of an European Union (EU) study. The end points to be assessed will be stimulation of beneficial bacteria (bifidogenic effects), increased short chain fatty acid production, beneficial effects on stool formation, and improvements in gut barrier function. Additionally, benefits of the LMWPs towards blood glucose levels (short term and acute) will be assessed.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy individuals
- Age 18-55 years
- Non smoking
- BMI >20 and <35kg/m2
Exclusion criteria
- Smoker
- Pregnant and lactating women
- Vegetarians and vegans
- Lactose intolerant individuals
- Diabetes
- Cardiovascular disease
- Autoimmune/ inflammatory disorders
- History of neoplasm
- Recent acute illness and/or chronic prescribed or self-prescribed use of anti-inflammatory agents (including aspirin)
- Use of broad spectrum antibiotics
- Use of drugs active on gastrointestinal motility or laxatives
- Use of dietary supplements (specifically probiotics or prebiotics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment 1
|
Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
|
Experimental: Treatment 2
|
Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
|
Placebo Comparator: Treatment 3
|
Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in faecal bacterial composition
Time Frame: up to 28-day treatment period (six/participant in total)
|
Fluorescent in situ hybridisation
|
up to 28-day treatment period (six/participant in total)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short chain fatty acid concentrations
Time Frame: up to 28-day treatment period (six/participant in total)
|
Gas Chromatography
|
up to 28-day treatment period (six/participant in total)
|
Faecal water barrier function bioactivity
Time Frame: up to 28-day treatment period (six/participant in total)
|
Trans-epithelial electrical resistance
|
up to 28-day treatment period (six/participant in total)
|
Bowel habits
Time Frame: 7 days following each faecal sample provision (six diaries/participant in total)
|
Faecal diary
|
7 days following each faecal sample provision (six diaries/participant in total)
|
Faecal characteristics
Time Frame: up to 28-day treatment period (six/participant in total)
|
Faecal sample type by inspection (Bristol Stool Chart)
|
up to 28-day treatment period (six/participant in total)
|
Faecal output weight
Time Frame: up to 28-day treatment period (six/participant in total)
|
Total faecal output weight
|
up to 28-day treatment period (six/participant in total)
|
Faecal pH
Time Frame: up to 28-day treatment period (six/participant in total)
|
pH meter
|
up to 28-day treatment period (six/participant in total)
|
Food intake
Time Frame: 4 days prior to each faecal sample provision (six diaries/participant in total)
|
Food diary analysed using a Food Composition Database
|
4 days prior to each faecal sample provision (six diaries/participant in total)
|
Acute glycaemic response on subset of volunteers (n=20)
Time Frame: Two days (mornings) following crossover intervention study
|
Oral glucose tolerance test following 1.Glucose + Alginate H1CC2012, or 2. Glucose
|
Two days (mornings) following crossover intervention study
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- REC/09/003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Agar H1CC2013
-
Showa Inan General HospitalCompleted
-
Assiut UniversityUnknownFungal Infection
-
Sohag UniversityRecruitingPseudomonas AeruginosaEgypt
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineRecruitingLiposarcoma | Liver Cancer | Rhabdomyosarcoma | Wilms Tumor | Malignant Rhabdoid Tumor | Yolk Sac TumorUnited States
-
Swiss Tropical & Public Health InstituteInstitute of Tropical Medicine, Belgium; B.P. Koirala Institute of Health Sciences and other collaboratorsCompletedShigellosis | Schistosomiasis | Strongyloidiasis | Dientamoebiasis | Giardiasis | Amoebiasis | Soil-transmitted Helminthiasis | Intestinal Salmonellosis | Campylobacteriosis | Aeromonas Spp. Infections | Cryptosporidium Spp. InfectionsCôte D'Ivoire, Indonesia, Mali, Nepal
-
Universidad de GuanajuatoAntisepsia CentralCompleted
-
Universidad de GuanajuatoAntisepsia CentralCompleted